Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Heat-labile enterotoxin (LT) is a potent AB5-type protein toxin produced by enterotoxigenic Escherichia coli (ETEC), a leading cause of traveler's diarrhea and neonatal diarrhea in developing countries (StatPearls, 2023). The toxin consists of a single A-subunit with enzymatic activity and a pentameric B-subunit responsible for binding to GM1 ganglioside receptors on host intestinal cells (UniProt, 2024). Upon internalization, the A-subunit ADP-ribosylates the Gs alpha subunit, causing permanent activation of adenylate cyclase and a subsequent surge in cyclic AMP levels (PubMed, 2022). This signaling cascade triggers the opening of chloride channels, leading to the profuse watery diarrhea characteristic of ETEC infection. Beyond its role in pathogenesis, the B-subunit (LTB) is highly immunogenic and is utilized in vaccine development, such as in the oral vaccine Dukoral, while the whole toxin is frequently studied as a mucosal adjuvant due to its ability to enhance immune responses to co-administered antigens (EMA, 2023; Journal of Immunology, 2021).
The B-subunit pentamer binds to GM1 ganglioside receptors on the surface of intestinal epithelial cells, facilitating the entry of the A-subunit. Once inside, the A-subunit catalyzes the ADP-ribosylation of the Gs alpha subunit of the heterotrimeric G protein, leading to the constitutive activation of adenylate cyclase. This results in elevated intracellular levels of cyclic AMP (cAMP), which activates protein kinase A and subsequently the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel, causing massive secretion of water and electrolytes into the intestinal lumen.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Heat-labile enterotoxin of enterotoxigenic Escherichia coli (LT).